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Abstract
Due to the rapidly evolving COVID-19 pandemic caused by the SARS-CoV-2 virus, quick public
health investigations of the relationships between behaviours and infection risk are essential. Recently
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the test-negative design was proposed to recruit and survey participants who are being tested for SARS-
CoV-2 infection in order to evaluate associations between their characteristics and testing positive on the
test. It was also proposed to recruit additional untested controls who are part of the general public in
order to have a baseline comparison group. This study design involves two major challenges for statistical
risk factor analysis: 1) the selection bias invoked by selecting on people being tested and 2) imperfect
sensitivity and specificity of the SARS-CoV-2 test. In this study, we investigate the nonparametric
identifiability of potential statistical parameters of interest under a hypothetical data structure, expressed
through missing data directed acyclic graphs. We clarify the types of data that must be collected in order
to correctly estimate the parameter of interest. We then propose a novel inverse probability weighting
estimator that can consistently estimate the parameter of interest under correctly specified nuisance
models.
1 Introduction
Under the current pandemic caused by the SARS-CoV-2 virus, where the resulting illness is referred to as
COVID-19, it is challenging to implement fast epidemiological inquiries to map and understand the disease.
Highly infectious1 in a completely non-immune population and targeting primarily the respiratory system
with clinical symptoms that include fever, cough, and fatigue,2,3 this illness continues to cause substantial
morbidity and mortality, straining the healthcare systems of many countries. With the aim of reducing
infection, global campaigns encourage individuals to modify their daily behaviour by measures which include
physical distancing, the use of masks, and intensified hygienic practices. Much interest lies in establishing
whether these interventions are effective at reducing infection probabilities at an individual or population
level.
Given the challenges involved in testing large portions of the population for active infection with SARS-
CoV-2, cases in the general public are typically ascertained through testing sites. In Canada, though regula-
tions have varied by epidemic stage and jurisdiction,4 in order to obtain a test, individuals may be required
to be experiencing symptoms of COVID-19 and/or have other reason to believe that they are infected, such
as being a healthcare worker. Thus, if potential study participants are recruited at test centers, the resulting
study cohort will not be representative of the general population at risk for the disease. Further, due to
the nature of testing self-selection, associations measured between participant covariates (e.g. demographics,
Conflicts of interest statement: Joanna Merckx is an employee of bioMe´rieux. This work is unrelated to her function as
Director Medical Affairs, bioMe´rieux Canada, Inc. The other authors have declared no conflict of interest.
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characteristics, and behaviours) and outcomes will not necessarily be representative of true causes or even
predictors of infection.5
Recently, Vandenbroucke et al.6 proposed a a modified case-control design that combines a test-negative
design, best known from its use in vaccine effectiveness research,7,8 with the recruitment of additional
population controls in order to identify risk/preventive factors of SARS-CoV-2 infection. This study design
involves both the recruitment of patients who are seeking testing for SARS-CoV-2 infection and of untested
individuals in the general population. They propose a matching approach to compare differences in study
participant covariates between people who test positive, people who test negative, and people who are not
seeking testing in order to triangulate factors that likely increase or decrease the odds of infection. Karmakar
and Small9 proposed a more efficient test to compare factors between the three groups. However, neither of
these studies addresses the problem from a missing data perspective while dealing with potential selection
bias of having two groups of participants who received testing based on outcome-related symptoms.
In this methodological study, we give a specific definition of the parameters of interest in a “risk/preventive
factor” analysis, corresponding to modeling the covariates that are predictive of SARS-CoV-2 infection in a
regression model. We then provide identifiability conditions under the test-negative design and an assumed
structural setting in the context of the COVID-19 pandemic. Identifiable means that we would know the
exact value of the parameters of interest if we had an infinite sample size; our study thus gives some conditions
under which identifiablity is achieved. Identifiability is of great importance because without this guarantee,
we cannot construct a consistent estimator under the given assumptions. Finally, we propose an inverse
probability weighting (IPW) estimator10–12 of the parameters of interest that may be feasible in this setting.
We evaluate this approach through simulation study and compare it with a naive approach to estimation
that does not incorporate untested population controls.
2 The Test-Negative Study Design with Population Controls
Given access to the recruitment of people seeking SARS-CoV-2 tests at a given testing site, we consider
a study design that involves the recruitment of two groups of people: (1) people who are being tested for
SARS-CoV-2 at the test site and (2) members of the general population, possibly selected as matched pairs
for those being tested, who are not seeking testing but who are under the jurisdiction of the test site. It must
be the case that members of group (2) would be able to access the test site were they to have symptoms
of COVID-19 or otherwise qualify for and seek testing. Participants recruited from group (1) are denoted
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R = 1 and those from group (2) are denoted R = 0. This is essentially a case-control study design except
that cases are those who are tested and controls are those who are untested. We assume random sampling
of independent members of both groups, with a total sample size of n. The need for independence implies
that, for example, only one member per household should be recruited.
All participants are given a questionnaire to collect information about the potential risk/preventive
factors under study, X, which we will now refer to simply as risk factors, and related confounders, C. The
questionnaire may also capture information about current symptoms related to COVID-19, W . It is also
necessary that we receive the result of the SARS-CoV-2 test from those being tested. The test result is
denoted Y (1=positive; 0=negative), which is only observable for those who are being tested (R = 1).
Recruitment from groups (1) and (2) will give us three categories of participants to contrast: those being
tested and who test positive for COVID-19, those being tested and who test negative for COVID-19, and those
not being tested. In principle, the comparison of the covariates (X) between test-positives and negatives
will allow us to see which risk factors differ between people who have become infected with SARS-CoV-2
versus those who haven’t and we can then compare to the controls from the general population.6 But simple
contrasts of tested participants may not estimate an interpretable parameter. In fact, the interpretation of
any measured associations relies on certain structural assumptions and the collection of necessary data that
would allow for the credibility of these assumptions. We expand on these concepts in the remainder of the
paper.
3 Parameters of interest
Our scientific objective is to identify risk factors, i.e. behaviours or characteristics of individuals that
are associated with COVID-19 in a chosen outcome regression model, possibly after adjustment for other
suspected confounders of these risk factors.13,14 The population of interest is members of the general public,
who were not previously infected with SARS-CoV-2 (i.e. who are at risk of infection), and who are under
the jurisdiction of the COVID-19 testing site under study, but who may or may not be seeking testing. The
regression model thus represents the associations between the risk factors and prospective short-term risk of
infection with SARS-CoV-2 in this population.
The binary outcome of interest is infection with SARS-CoV-2, denoted Y 1. Due to imperfect test
sensitivity and specificity, this outcome may not correspond with Y , the result of the test for COVID-
19. Sensitivity is defined as the probability of testing positive when truly infected. Specificity is defined
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as the probability of testing negative when not infected. The observed data are thus of the form O =
(X,C,W , R, Y ). The complete data under knowledge of the true outcomes are (X,C,W , R, Y 1). Under
a perfect test for COVID-19 (i.e. sensitivity and specificity equal to one), Y = Y 1 when R = 1 in which
case the observed data with outcome censoring can be written as O∗ = (X,C,W , R,R× Y 1). We will use
lower case letters to represent realizations of these random variables. In particular, oi = (xi, ci,wi, ri, yi)
for i = 1, ..., n where n is the total sample size.
We then define a logistic regression model
logit{Pr(Y 1 = 1 |X = x,W = w)} = xtβ + ctγ (1)
= β0 + β1x1 + β2x2 + ...+ βrxr + γ1c1 + γ2c2...+ γscs
where X = (1, X1, X2, ..., Xr), C = (C1, C2, ..., Cs) (and similarly for the realizations denoted by lower
case letters), β = (β0, β1, ..., βr), and γ = (γ1, γ2, ..., γs), under a typical log-likelihood loss function. Our
interest lies in the vector parameter β where exp(βk) corresponds to the conditional odds ratio related to
the covariate Xk.
Importantly, the parameters in this regression model may not represent causal effects, i.e. even if a
coefficient βk is negative, it does not necessarily mean that Xk decreases the risk of infection.
13,14 In order
to establish such a relationship, all confounders of the effects of risk factors on the outcome must be adjusted
for in the model, the model must correctly represent the mechanisms of infection, and all risk factors must
be independently manipulable. While we could extend this work to consider these aspects, for simplicity
we retain β as the statistical parameter of interest in this study; in practice its estimation may provide
important insights into the variables related to SARS-CoV-2 infection or ways that high-risk individuals
may be identified. The remainder of the article addresses the estimation of the statistical parameter β
within the regression model.
4 Potential for Collider Bias Resulting from Selecting Patients at
Test Sites
The challenge in comparing patients who tested positive versus negative arises from selecting on patients
who seek testing.
Figure 1 is a missing data directed acyclic graph (mDAG)15,16 representing assumed relationships between
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covariates in this analysis. In particular, we allow for the baseline covariates to potentially cause (i.e.
influence the risk for) SARS-CoV-2 infection, Y 1. If a patient seeks testing (R = 1) then we observe a test
result Y . If the test can perfectly detect infection, then Y = Y 1 if R = 1 and Y = NA if R = 0. Testing
is typically obtained if the individual has suspected symptoms of COVID-19, W (which may include fever,
respiratory symptoms, etc) but the act of seeking and then receiving testing may also be affected by the
risk factors (X) and other baseline covariates (C). For example, an alert individual who frequently hand
washes may be more inclined to seek testing, possibly also depending on whether they are experiencing real
or perceived symptoms of COVID-19 (included in W ). Any variable in X, such as recent travel, that places
a person at higher risk for infection may also prompt that person to seek testing, even with absent or mild
symptoms. We assume that true infection only affects test-seeking behaviour through symptoms. Thus, in
W we include all symptoms known to the participant. W may also represent symptoms of other (respiratory
or other) infections, and these may be caused by pathogens other than the SARS-CoV-2 virus.
Other unmeasured factors may modify the risk of COVID-19, Y 1. We allow for unmeasured causes
(omitted from graph for simplicity) of both COVID-19 and other infections. In constructing this mDAG, we
also assume that no unmeasured factor simultaneously affects any pair of nodes. We will discuss and relax
some of these assumptions in Section 5.
The objective of our analysis is to estimate the model parameters representing the relationship between
X and Y 1 while adjusting for C, i.e. the parameters of the model for Pr(Y 1 = 1 | X = x,C = c). But
because we only have outcome data from those who are seeking testing, we may consider directly modeling
the observed outcomes among those who were tested Pr(Y = 1 | X = x,C = c, R = 1). Even under a
perfect test for COVID-19, so that Y 1 = Y when R = 1, such modeling of the selected population may
produce misleading associations between X and Y . This is due to collider bias,5,18 which is caused by
subsetting or adjusting for a variable that is caused by the two variables whose association is of interest. In
our case, we would be conditioning on R = 1, which is caused by both Y 1 (through W ) and by X. Thus,
there is a possibility for erroneous conclusions resulting from the measured associations between X and Y
among those seeking testing.
For example, having access to a private vehicle allows you to avoid public transit, which may be a
preventive factor for viral infection. Thus we may be interested in measuring the association between access
to a private car and COVID-19. However, access to a COVID-19 test site is also facilitated by access to
a vehicle, especially for those living further away from the test sites. Because (we are supposing) those
with a car are more likely to be able to seek testing if they have symptoms, there is a disproportionate
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number of people without cars with COVID-19 who are not tested. Thus, we may measure a negative
association between access to a private vehicle and COVID-19 even if there is no causal relationship between
car ownership and COVID-19. We also demonstrate this by example in the simulation study.
5 Identifiability of Risk Factors in the General Population
In this section, we discuss the identifiability of the parameters of the model in equation (1) under the mDAG
in Figure 1. We then discuss identifiability under some less restrictive assumptions. When identifiability
holds, a maximum likelihood substitution estimator19 and an IPW estimator can be constructed.
5.1 Identifiability under the graph in Figure 1
The mDAG in Figure 1 makes several important assumptions. In particular, it assumes that W is fully
measured, meaning that we measured all symptoms caused by SARS-CoV-2 infection that may lead to
seeking testing. This can be achieved by thorough harmonized data collection on individuals being recruited
from both populations. We assume that Y is equal to Y 1 when R = 1 up to random error. As mentioned,
we allow for unmeasured common causes of Y 1 and other infections. Otherwise, we assume that there are
no common causes of any pair of nodes in the graph.
As a consequence of this structure, we have the independence condition
R ⊥ Y 1 |X = x,C = c,W = w. (2)
We then use the law of total probability to write our association of interest as
Pr(Y 1 = 1 |X = x,C = c) =
∫
w
Pr(Y 1 = 1 |X = x,C = c,W = w)fW |X,C(x, c)dw
=
∫
w
Pr(Y 1 = 1 |X = x,C = c,W = w, R = 1)fW |X,C(x, c)dw (3)
by the independence assumption (2). The quantity fW |X,C(x, c) is the possibly multivariate distribution of
W conditional onX = x and C = c and the multiple integrals are taken over the domain of this distribution.
If the SARS-CoV-2 test is perfect then we can replace the Y 1 by Y directly. If not, assuming uniform
test sensitivity σ and specificity ρ independent of patient characteristics, under the condition that σ+ρ > 1,
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the law of total probability expanding on Y and rearranging terms gives us
Pr(Y 1 = 1 |X = x,C = c,W = w, R = 1) = Pr(Y = 1 |X = x,C = c,W = w, R = 1) + ρ− 1
σ + ρ− 1 , (4)
which is estimable from the data of the tested subjects.20
For the distribution in equation (3), we may write
fW |X,C(x, c) = fW |X,C,R=1(x, c)︸ ︷︷ ︸
(a)
Pr(R = 1 |X = x,C = c)︸ ︷︷ ︸
(c)
+ fW |X,C,R=0(x, c)︸ ︷︷ ︸
(b)
Pr(R = 0 |X = x,C = c)︸ ︷︷ ︸
1−(c)
(5)
where fW |X,C,R=r(x, c) is the conditional distribution of W in the population corresponding to R = r for
r = 0, 1. Components (a) and (b) are estimable from the subjects from the tested and untested populations,
respectively. For component (c), the case-control design of sampling tested and untested patients allows
us to identify associations between R and (X,C). However, case-control data do not give us a baseline
prevalence of the outcome (R in this case). Therefore, it is only under external knowledge of the marginal
Pr(R = 1), the prevalence of testing, that component (c) is identified.21
Because we are able to relate the target probability Pr(Y 1 |X = x,C = c) to quantities that are known
if given infinite samples of the observed data structure, under the given assumptions, we have established
identifiability. This result does not rely on the specification of parametric models. Thus, for identifiability
we need complete data on the symptoms W (specifically, all variables caused by Y 1 leading to testing) in
addition to the covariates of interest (X,C). These covariates must include all common causes of testing
and Y 1 and/or W (see next section). We also require knowledge of the parameters Pr(R = 1), σ, and ρ.
5.2 Identifiability in settings with fewer restrictions
The assumed relationships in the mDAG of Figure 1 may be too restrictive in certain studies. We thus
describe several specific generalizations of the above graph and the consequences on identifiability and in-
terpretability of the β parameter.
5.2.1 Unmeasured variable affecting test seeking which also affects Y 1 and/or W
In Figure 2 we add an unmeasured variable U that is a factor influencing the act of getting tested which acts
independently of all other variables in the graph. Suppose that U also affects being infected with SARS-CoV-
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2 or having symptoms of COVID-19 or both. For instance, mold exposure is associated with living in lower
income neighborhoods.22 Mold exposure may lead to respiratory symptoms (e.g. asthma exacerbation) that
could be confused for COVID-19 symptoms. People living in lower income neighborhoods may be more at
risk of COVID-19 due to greater population density and greater proportions of people who work in “essential
services”.23 Thus, socio-economic status may be such a variable if it is not included in X or C. A second
example is any variable that makes an individual high-risk (arrow into Y 1) that also leads to testing even if
the individual is symptom free.
The consequence of such a variable is that independence condition (2) no longer holds. This is because
U directly creates dependence between R and Y 1 and/or adjusting for W , which is a collider of Y 1 and U ,
creates the dependence between R and Y 1. Thus, if such a variable U exists we cannot use the described
maximum likelihood procedure. We should therefore attempt to measure all such factors and include them
in X or C.
5.2.2 Unmeasured symptoms of COVID-19 leading to testing
Another potential scenario involves symptoms U of COVID-19 that were not included in W but can also
lead to testing. This scenario is portrayed in Figure 3. Such a variable may exist if, for instance, a study
does not ask about the less common symptoms of COVID-19, such as headache or skin rashes.
In this scenario, U is a mediator of the effect of Y 1 on R so the independence condition (2) does not hold.
This is still the case if U is related to the baseline covariates or partially correlated with other symptoms.
5.2.3 Unmeasured variables correlated with baseline covariates and cause of testing
Consider the presence of a variable U affecting R and correlated with baseline covariates (either by causal
relationship or other). Such a variable does not affect the independence condition (2) and thus identifiability
is preserved. Such variables include demographic information and participant characteristics that affect
test-seeking behaviour but are otherwise not related to infection or symptoms.
5.2.4 Unmeasured variables affecting risk factors and COVID-19 infection
In the presence of a variable U that affects both X and Y 1, the association between risk factors and outcome
of interest will be confounded. However, the presence of such a variable will not affect the independence
condition (2) and thus the parameters β in model (1) will still be identifiable. However, their values
may be less meaningful and not represent causal relationships between risk factors and infection due to the
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unmeasured confounding.
6 Estimation with IPW
The g-formula relates the observed data to Pr(Y 1 |X = x,C = c) and thus the model of interest. Estima-
tion is available in principle through modeling the components of the g-formula, producing a substitution
estimator.24 We find that when W is high-dimensional, as is likely the case in this setting, the g-formula
estimator may not be feasible. Alternatively, one may model the probability of selection directly using the
case-control data of tested and untested individuals to construct an estimator using IPW.12,21 We describe
the latter, which requires knowledge of the test sensitivity, σ, and specificity, ρ, and the value of testing
prevalence Pr(R = 1). If these parameters are uncertain, then one can undertake a sensitivity analysis by
varying the assigned values.
The IPW estimator for the parameters of interest in model 1 is given through the score equations of a
weighted logistic regression
n∑
i=1
xi
ci
 I(ri = 1){QˆY 1,R=1(xi, ci,wi)− expit(xiβ + ciγ)}
Pˆ r(R = 1 |X = xi,C = ci,W = wi)
= 0 (6)
where values (xi, ci,wi, ri) refer to the data realizations of subject i.
In order to estimate the numerator of the IPW estimator, we must first define a model for Pr(Y = 1 |
X = x,C = c,W = w, R = 1). This model is fit on subjects who received a test. Predictions from this
model fit are denoted QˆY,R=1(x, c,w). By the relationship in equation (4), we set
QˆY 1,R=1(x, c,w) = {QˆY,R=1(x, c,w) + ρ− 1}/(σ + ρ− 1)
for all subjects with R = 1. Note that QˆY 1,R=1(x, c,w) approximates Pr(Y
1 = 1 | X = x,C = c,W =
w, R = 1).
In order to estimate the denominator of (6), we note that the associations between covariates, symptoms,
and the probability of testing must be estimated from the data resulting from the case-control design, where
sampling is carried out in both the tested and untested groups. If we know the baseline testing prevalence
q0 = Pr(R = 1), we may use a simple weighting method for case-control studies.
21 Specifically, we assign all
cases the weight q0 and all controls the weight (1− q0)/J where J is the ratio of the number of controls to
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cases in the sample. We use these weights in any chosen binomial regression model for R conditional on X,
C, and W . Finally, we use predictions from this model fit to estimate Pˆ r(R = 1 | X = x,C = c,W = w)
for all tested subjects.
A simple proof of the consistency of this estimator under the independence assumption (2) is given in
the Appendix. It is required that the models for QY,R=1(x, c,w) and Pr(R = 1 | X = x,C = c,W = w)
are both correctly specified. We expect that some values of the denominator may be close to one for some
tested subjects who are experiencing several symptoms of COVID-19. However, we would not necessarily
expect denominator values close to zero because the IPW equation (6) only uses subjects who did, in fact,
get tested. We thus expect our IPW estimator to be fairly stable in this setting.
7 Simulation Study
In order to evaluate the proposed IPW method under the mDAG in Figure 1, and compare it to a naive
approach, we perform a simulation study. We evaluate the method under ideal circumstances, where the
assumed parametric models are close to well-specified, where sensitivity and specificity of the test are known,
and where the baseline prevalence of testing is known. We then evaluate the sensitivity to departures from
these assumptions.
We first simulate ordered data O+ = (C,X, Y 1,W,R, Y ), where each variable is unidimensional, for a
population of 1,000,000. Baseline confounder C is generated from a standard Gaussian distribution. The risk
factor of interest, X, is generated as a Bernoulli random variable conditional on C such that its prevalence
in the population is approximately 10%. True COVID-19 status Y 1 is generated as Bernoulli conditional on
X and C such that the true incidence of acute infection in this previously untested population is 10% overall
(for this example, though this is likely lower in the general population in practice). The true conditional
association between X and Y 1 is exp(β) = 1.5. Symptoms W are Bernoulli conditional on C, X, and Y 1,
where the dependence on Y 1 is strong so that infected individuals have a high probability of experiencing
symptoms (roughly between 0.5 and 0.9). Testing status R is then generated given C, X, and W with a
fairly strong dependence on W such that symptoms lead to a higher probability of being tested. Given the
true test infection state Y 1, true sensitivity σ = 0.95 and specificity ρ = 0.99, test outcome Y is drawn
for all tested subjects. Then, we randomly sample 2000 tested participants (roughly all available) and 2000
untested participants (a small subsample of the total available) from the population, which gives us our
study sample. The data generation is given in Appendix Table B.
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In order to demonstrate the selection bias from using only tested subjects to evaluate risk factors, we fit
a logistic regression for Y conditional on C and X using the data from tested subjects in the sample. We
then apply our method using logistic regressions for QY,R=1(x, c, w) and Pr(R = 1 | X = x,C = c,W = w),
where the latter regression is weighted using the case-control weights. The score equations (6) are then
solved using a standard optimization procedure for logistic regressions with a log-likelihood loss function,
though our implementation allows for values of QˆY 1,R=1(x, c, w) that are outside of (0,1) which occurs due
to the transformation with σ and ρ.
We implement our method with correctly specified logistic regression models under the following settings:
assumed values (σˆ, ρˆ) set to (0.95, 0.99) (i.e. truth), (1, 1), and (0.99, 0.95); assumed testing prevalence qˆ0
set to truth (roughly 0.2% of the full population), truth ×10, and truth ×100. We then misspecify our
testing model by omitting an interaction term between X and W . In the last IPW implementation, we do
not adjust for symptoms by removing W from all models.
We use a case-control nonparametric bootstrap method, where resampling with replacement is done
separately in the tested and untested groups, to estimate the standard error and 95% confidence intervals
for the IPW method.25 The usual logistic regression standard errors are used for the naive method. All
simulations were run with R statistical software v. 3.6.1.26
The results of all implementations in addition to the analysis conducted only on tested subjects are given
in Table 1. Mean parameter estimates, mean standard error estimates, Monte Carlo standard errors, and
% coverage of the 95% confidence intervals are given. We first note that the logistic regression analysis
run with only tested subjects is highly biased, suggesting on average that X leads to a lower risk of the
outcome while the opposite is true. IPW implemented with correct parameter values and models had no
error on average, with a bootstrap variance estimate that corresponded to the Monte Carlo value and only
slight undercoverage from the 95% bootstrap confidence interval. Ignoring the sensitivity and specificity (i.e.
setting σˆ = ρˆ = 1) in the IPW method led to some attenuation in the average estimate though coverage
remained similar. Incorrectly specifying σˆ = 0.99 and ρˆ = 0.95 resulted in substantial overestimation and
inflated standard error estimates. Misspecifying qˆ0 by an order of 10 did not lead to important bias, but
misspecifying by an order of 100 led to underestimation. Missing an interaction in the model for testing led
to an inverted odds ratio suggesting that X is protective for Y 1. This result points to the importance of
correct modeling of the nuisance functions in the IPW estimator. Finally, when not adjusting for W , IPW
gives the same biased results as the subsetted logistic regression. Bias occurs because if we omit W then we
do not satisfy the independence assumption (2) with the measured variables.
12
True OR exp(β) = 1.5 Mean MC Mean est % Cov
True σ = 0.95, ρ = 0.99 est SE SE
Analysis of tested subjects (R = 1) 0.87 0.18 0.17 10
IPW assumed assumed
sens, spec prevalence of R
Correct models σˆ = 0.95
ρˆ = 0.99
qˆ0=truth 1.49 0.24 0.24 92
σˆ = 1
ρˆ = 1
qˆ0=truth 1.43 0.22 0.22 91
σˆ = 0.99
ρˆ = 0.95
qˆ0=truth 2.19 0.39 0.82
a 86
σˆ = 0.95
ρˆ = 0.99
qˆ0=truth×10 1.46 0.24 0.24 91
σˆ = 0.95
ρˆ = 0.99
qˆ0=truth×100 1.26 0.21 0.20 80
Missing interaction σˆ = 0.95
ρˆ = 0.99
qˆ0=truth 0.79 0.29 0.29 27
Omitted W σˆ = 0.95
ρˆ = 0.99
qˆ0=truth 0.86 0.19 0.19 11
Table 1: Aggregate results of the application of each method and implementation on 1000 simulated datasets
of 2000 controls and approximately 2000 cases. Mean est: exponential of the mean estimate of β (i.e.
transformed to the OR scale); MC SE: Monte-Carlo standard error of βˆ; Mean est SE: square-root of the
mean estimated variance of βˆ; % Cov: % of 95% confidence intervals that contain the true β (optimal is
95%). a median used due to large amount of inflated bootstrap estimates.
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8 Discussion
In this paper, we have contributed to the investigation of statistical analysis under the test-negative design
in the context of evaluating risk or preventive factors of COVID-19 when participants may be conveniently
recruited at disease testing sites. We defined a potential parameter of interest in such a study as the
coefficients in a regression model for the true infection outcome. We explained and demonstrated the
importance of sampling additional population controls6 in order to avoid selection bias from comparing only
tested individuals. We then investigated the identifiability of the target parameter under several settings.
Finally, we proposed a novel IPW estimator that accounts for both imperfect test sensitivity and specificity
and the study design. We then evaluated this estimator through simulation study.
There is a growing literature on identifiability conditions for statistical parameters under missingness27
and a large literature of identifiability of causal parameters.28,29 Our setting is somewhat different from
a typical missing data setting in that, because observed outcomes are obtained through imperfect tests,
true infection status is not observed for any subject. In addition, the case-control component of the study
design must be considered when estimating all probabilities and distributions in the general population of
interest. These results are important as they shed light on the data collection needed to correctly estimate
the parameter of interest. In particular, we must measure all variables on the pathway between SARS-CoV-2
infection and testing. This means that incomplete ascertainment of the symptoms leading some individuals
to be tested would result in a biased estimator. We must also measure and adjust for all causes of testing if
they are also causes of SARS-CoV-2 infection and/or symptoms.
The estimator proposed assumes knowledge of the test properties and the prevalence of testing in the
population. Given the potential sensitivity to errors made when specifying these quantities, one could
undertake a sensitivity analysis. Specifically, confidence intervals could be constructed using all combinations
of credible values for σ, ρ, and q0. By taking the minimum confidence interval lower bound and the maximum
upper bound, we can place bounds on the set of parameter values that are supported by the data and
assumed model. Other approaches may involve Bayesian estimation30 where informed priors are placed on
these values, but we do not explore such approaches here. We also noted the sensitivity of the results to
misspecification of the model for testing. It is thus important to understand the mechanisms driving people
to seek and receive testing and to use a flexible modeling approach.31
This work can be directly adapted to an investigation of causality by modifying the target parameter
of interest to a causal parameter under additional assumptions including “no unmeasured confounders” for
an exposure of interest . If the additional assumptions hold, then this approach could investigate potential
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epidemiological causes of SARS-CoV-2 infection. Future work could also improve the efficiency of the IPW
estimator through such approaches as targeted maximum likelihood estimation.32 Though improvements are
likely possible, a practical fully efficient estimator is probably infeasible due to the difficulties in applying
the g-formula.
Due to the rapidly evolving nature of the COVID-19 pandemic, studies with short timelines are necessary
to monitor public health. The accessibility of the test-negative design with untested controls allows for much
shorter timelines compared to a cohort study of uninfected individuals. We must however overcome the
inherent selection bias arising from this design. Novel study designs must be followed by clear definitions of
parameters of interest, investigations of identifiability of these parameters, and potentially tailored estima-
tors. These steps allow for a principled approach that does not solely rely on intuition and may help avoid
substantial sources of bias when tracking risk and preventive factors of COVID-19.
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A Consistency of IPW
By the definition of the parameters (β,γ) in equation (1) and the typical log-likelihood loss function, the
true values are defined through the equations
E

X
C
{Y 1 − expit(Xβ +Cγ)}
 = 0. (7)
We first assume that the model for QY,R=1(x, c,w) is consistent such that the values for given (xi, ci,wi)
converge to the truth. Then, the estimates QˆY 1,R=1(x, c,w) will converge to the true Pr(Y
1 = 1 | X =
xi,C = ci,W = wi) as long as the parameters σ and ρ are correct. Then, as n goes to infinity, and assuming
consistent nuisance function estimation in the denominator, the IPW score equations (6) imply
E

X
C
 I(R = 1){Pr(Y 1 = 1 |X,C,W )− expit(Xβ +Cγ)}
Pr(R = 1 |X,C,W )
 = 0.
By iterative expectations, we can rewrite the above as
E
E

X
C
 I(R = 1){Pr(Y 1 = 1 |X,C,W , R = 1)− expit(Xβ +Cγ)}
Pr(R = 1 |X,C,W )
∣∣∣∣X,C,W

 = 0,
=⇒ E

X
C
 Pr(R = 1 |X,C,W )
Pr(R = 1 |X,C,W )
{
Pr(Y 1 = 1 |X,C,W , R = 1)− expit(Xβ +Cγ)}
 = 0,
=⇒ E

X
C
{Pr(Y 1 = 1 |X,C,W )− expit(Xβ +Cγ)}
 = 0 by ignorability,
=⇒ E

X
C
{Y 1 − expit(Xβ +Cγ)}
 = 0.
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B Simulation study data generation
The data-generating mechanism used in the simulation study is given in Table B. We also present the R
code below.
popsize=1000000
C<-rnorm(n=popsize)
X<-rbinom(prob=plogis(-2.3+0.3*C),size=1,n=popsize) #prevalence is around 0.1
#Y will be censored, Y1 is latent for everyone
Y1<-rbinom(prob=plogis(log(OR)*X+0.5*C-2.7),size=1,n=popsize)
#check desired prevalence of true outcome
#generate test results
Y<-rbinom(prob=(sens*Y1+(1-spec)*(1-Y1)),size=1,n=popsize)
#symptoms based on infection
W<-rbinom(n=popsize, prob=plogis(-2+0.2*C+0.5*X+3*Y1),size=1)
#selection on outcome for testing
R<-rbinom(n=popsize, size=1, prob=plogis(-7+2*W+0.6*X+0.2*C-W*X))
#about 0.002 of pop tested -> determines sample size
q0<-mean(R) #Pr(R=1) in population
Y[R=0]<-NA
indcontrols<-sample(1:sum(R==0),size=2000,replace=F)
indcases<-sample(1:sum(R==1),size=min(sum(R==1),2000),replace=F)
dat<-as.data.frame(rbind((cbind(C,X,Y,W,R,Y1)[R==1,])[indcases,],
(cbind(C,X,Y,W,R,Y1)[R==0,])[indcontrols,]))
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Variable Generating Mechanism (i.i.d)
C C ∼ N(mean = 0, sd = 1, n = 1000000)
X X ∼ Bern(prob = expit(−2.3 + 0.3C), n = 1000000)
Y 1 Y 1 ∼ Bern(prob = expit(−2.7 + log(1.5)X + 0.5C), n = 1000000)
W W ∼ Bern(prob = expit(−2 + 0.2C + 0.5X + 3Y 1), n = 1000000)
R R ∼ Bern(prob = expit(−7 + 2W + 0.2C + 0.6X −WX), n = 1000000)
q0 q0 = mean(R)
Y Y ∼ Bern(prob = R{Y 1σ + (1− Y 1)(1− ρ)}, n = 1000000)
set Y = NA for all R = 0.
Subsample 2000 subjects with R = 0 and at most 2000 subjects with R = 1.
Table 2: The data generating mechanism used in the simulation study.
C R code to run the IPW estimator
In this section, we present the R code to run the estimator for observed data with structureO = (X,C,W,R, Y )
where X, C, and W are univariate. Note that the simulation study data has such a structure. This code
can be easily extended for multivariate versions of those variables.
The IPW function uses the following two helper functions.
#Log-bin function that can take Y values outside of (0,1)
LogLikelihood<- function(beta, Y, X,w){
pi<- plogis( X%*%beta ) # P(Y|A,W)= expit(beta0 + beta1*X1+beta2*X2...)
pi[pi==0] <- .Machine$double.neg.eps # avoid taking the log of 0
pi[pi==1] <- 1-.Machine$double.neg.eps
logLike<- sum( w*( Y*log(pi) + (1-Y)*log(1-pi) ) )
return(-logLike)
}
grad<- function(beta, Y, X, w){
pi<- plogis( X%*%beta ) # P(Y|A,W)= expit(beta0 + beta1*X1+beta2*X2...)
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pi[pi==0] <- .Machine$double.neg.eps # for consistency with above
pi[pi==1] <- 1-.Machine$double.neg.eps
gr<- crossprod(w*X, Y-pi) # gradient
return(-gr)
}
The function to run IPW depends on the data (dat) and values for sensitivity (sens), specificity (spec),
and the baseline prevalence (q0hat). The function follows.
IPWest<-function(dat,sens,spec,q0hat){
#Use IPW estimator (with true sens and spec) to estimate
modYR1<-glm(Y~C+W*X,subset=(R==1),family=binomial(),data=dat)
QY1R1<-(predict(modYR1,type="response",newdata=dat)+spec-1)/(sens+spec-1)
#cases
nC<-sum(dat$R==1)
#controls
nCo<-sum(dat$R==0)
J<-nCo/nC
#weights
w<-(1-q0hat)/J*(dat$R==0+0)+q0hat*(dat$R==1+0)
#case-control probability
#Specify some model for R, fit with weights w. We use a logistic regression as an example:
modRwxc<-glm(R~W*X+C,weights=w,family=binomial(),data=dat)
PRwxc<-predict(modRwxc,type="response")
Ystar=QY1R1[dat$R==1]
#This solves the IPW score equations by optimizing the log-likelihood
optim.out <- optim(par=c(-3,0.5,0.5), fn=LogLikelihood, gr=grad, Y=Ystar,
X=cbind(1,dat$X,dat$C)[dat$R==1,], w=1/PRwxc[dat$R==1], method="BFGS")
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beta<- optim.out$par[2]
#The score equations can also be solved with geeglm in geepack
#But we must truncate the outcome to (0,1)
#library(geepack)
#Ystar[Ystar<0]<-0
#modMSM<-geeglm(Ystar~X+C,data=dat[dat$R==1,],id=1:sum(dat$R),weights=1/PRwxc[dat$R==1],
family=binomial)
#est<-coef(modMSM)[2]
return(beta)
}
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Figure 1: mDAG representing hypothetical relationship between baseline covariates X and C, symptoms
W , seeking testing R, true infection Y 1, and observed test outcome Y . Note that Y 1 is observed with error
for tested subjects (R = 1). Drawn using DAGitty.17
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Figure 2: Presence of an unmeasured variable U that affects R and symptoms W and/or infection with
COVID-19, Y 1. Drawn using DAGitty.17
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Figure 3: Presence of unmeasured symptoms U of COVID=19 Y 1. Drawn using DAGitty.17
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